A clinical analysis of radiotherapy combined with temozolomide for postoperative high-grade glioma
Li Kaixin,Kong Yue,Dong Baiqiang,Zhamg Xiaoqian,Hua Yonghong,Shi Lei,Yang Ling,Chen Yuanyuan,Hu Qiaoying,Chen Ming
Department of Radiation Oncology,Affiliated Quanzhou First Hospital of Fujian Medical University,Quanzhou 362000,China (Li KX);Department of Radiation Oncology,Zhejiang Hospital,Hangzhou 310000,China (Kong Y,Dong BQ,Zhang XQ,Hua YH,Shi L,Chen YY,Hu QY,Chen M)Department of Oncology,Xinyu People’s Hospital,Xinyu 338000,China (Yang L)
Abstract：Objective To assess the efficacy and safety of three-dimensional radiotherapy (3DRT) combined with temozolomide (TMZ) for postoperative high-grade glioma (HGG), and to explore the prognostic factors for HGG patients. Methods A retrospective analysis was performed on the clinical data of 111 patients with postoperative HGG who were admitted to our hospital and received 3DRT combined with TMZ from 2008 to 2015. The efficacy and safety of the treatment were evaluated. The survival rate was calculated by the Kaplan-Meier method and analyzed by the log-rank test. A multivariate prognostic analysis was performed using the Cox model. Results The 1-, 2-, and 3-year sample sizes, overall survival (OS) rates, and progression-free survival (PFS) rates were//, 83.5%/46.9%/35.6%, and 52.2%/34.7%/26.4%, respectively. The common adverse reactions during chemoradiotherapy were acute neurotoxicity, hematologic toxicity, hepatotoxicity, and gastrointestinal toxicity, most of which were tolerable. Pathological grade was an independent prognostic factor for OS and PFS rates (P=,). Conclusions 3DRT combined with TMZ achieves satisfactory efficacy and safety in the treatment of patients with postoperative HGG. Pathological grade is an independent prognostic factor for patients with postoperative HGG.
. A clinical analysis of radiotherapy combined with temozolomide for postoperative high-grade glioma[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 133-137.
[1] Louis DN,Ohgaki H,Wiestler OD,et al. The 2007 WHO classification of tumours of the central nervous system[J].Acta Neuropathol,2007,114(2):97-109.DOI:10.1007/ s00401-007-0243-4. [2] ’s JL,Schwartzbaum JA,Wrensch M,et al. Epidemiology of brain tumors[J].Neurol Clin,2007,25(4):867-890.DOI:10.1016/j.ncl.2007.07.002. [3] Weller M,van den Bent M,Hopkins K,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma[J].Lancet Oncol,2014,15(9):e395-e403.DOI:10.1016/S1470-2045(14)70011-7. [4] Minniti G,Amelio D,Amichetti M,et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide[J].Radiother Oncol,2010,97(3):377-381.DOI:10.1016/ j.radonc.2010.08.020. [5] Kreth FW,Thon N,Simon M,et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy[J].Ann Oncol,2013,24(12):3117-3123.DOI:10.1093/annonc/mdt388. [6] Zinn PO,Colen RR,Kasper EM,et al. Extent of resection and radiotherapy in GBM:a 1973 to 2007 surveillance,epidemiology and end results analysis of 21,783 patients[J].Int J Oncol,2013,42(3):929-934.DOI:10.3892/ijo.2013.1770. [7] Omuro A,DeAngelis LM.Glioblastoma and other malignant gliomas:a clinical review[J].JAMA,2013,310(17):1842-1850.DOI:10.1001/jama.2013.280319. [8] Sun MZ,Oh T,Ivan ME,et al. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma[J].J Neurosurg,2015,122(5):1144-1150.DOI:10.3171/2014.9.JNS14193. [9] Bodensohn R,Corradini S,Ganswindt U,et al. A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients[J].Int J Clin Oncol, 2016,21(4):642-650.DOI:10.1007/s10147-015-0941-1. [10] Badiyan SN,Markovina S,Simpson JR,et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide[J].Int J Radiat Oncol Biol Phys,2014,90(4):877-885.DOI:10.1016/j.ijrobp.2014.07.014. [11] Stupp R,Hegi ME,Mason WP,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase Ⅲ study:5-year analysis of the EORTC-NCIC trail[J].Lancet Oncol,2009,10(5):459-466.DOI:10.1016/S1470-2045(09)70025-7. [12] Hegi ME,Diserens AC,Gorlia T,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J].N Engl J Med,2005,352(10):997-1003.DOI:10.1056/NEJMoa043331. [13] Darlix A,Baumann C,Lorgis V,et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma[J].Anticancer Res,2013,33(8):3467-3474. [14] Mao Y,Yao Y,Zhang LW,et al. Does early postsurgical temozolomide plus concomitant radiochemotherapy regimen have any benefit in newly-diagnosed glioblastoma patients？ A multi-center,randomized,parallel,open-label,phase Ⅱ clinical trial[J].Chin Med J,2015,128(20):2751-2758.DOI:10.4103/0366-6999.167313. [15] Cairncross G,Wang MH,Shaw E,et al. Phase Ⅲ trial of chemoradiotherapy for anaplastic oligodendroglioma:long-term results of RTOG 9402[J].J Clin Oncol,2013,31(3):337-343.DOI:10.1200/JCO.2012.43.2674. [16] van den Bent MJ,Brandes AA,Taphoorn MJB,et al. Adjuvant procarbazine,lomustine,and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma:long-term follow-up of EORTC Brain Tumor Group study 26951[J].J Clin Oncol,2013,31(3):344-350.DOI:10.1200/JCO.2012.43.2229. [17] Brandes AA,Franceschi E,Tosoni A,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J].J Clin Oncol,2008,26(13):2192-2197.DOI:10.1200/JCO.2007.14.8163.
2017, Vol. 26 
